Archive for the ‘unhelpful retraction notices’ Category
On November 11, St. Louis’s KTVI reported that krokodil, a nasty opioid concoction with roots in Russia, had arrived in their town. They based that report on a case study published in the American Journal of Medicine, “Krokodil’—A Designer Drug From Across the Atlantic, with Serious Consequences,” and interviewed two of the paper’s authors, Dany Thekkemuriyil and Unnikrishnan Pillai.
The case study involved a 30-year-old man the Thekkemuriyil and Pillai said they had seen at St. Mary’s Health Center in Richmond Heights, Missouri. As the St. Louis Post-Dispatch reported a few days later: Read the rest of this entry »
Two cancer researchers who hold a patent on a particular pathway that might be a target for new drugs — and one of whom leads a company that is studying those potential drugs — have retracted two related papers in the Journal of Biological Chemistry (JBC).
The notices for “Kinase suppressor of Ras signals through Thr269 of c-Raf-1“ and “The kinase activity of kinase suppressor of Ras1 (KSR1) is independent of bound MEK,” which share H. Rosie Xing and Memorial Sloan-Kettering’s Richard Kolesnick as authors, say the same thing: Read the rest of this entry »
The Journal of Clinical Anesthesia has a retraction of a 2006 paper by a group from Columbia University that, to our minds, is the poster child for how not to handle such things.
The article, “Dexmedetomidine infusion is associated with enhanced renal function after thoracic surgery,” was written by Robert J. Frumento, Helene G. Logginidou, Staffan Wahlander, Gebhard Wagener, Hugh R. Playford and Robert N. Sladen, who now is chief of critical care at the institution. The paper has been cited 30 times, according to Thomson Scientific’s Web of Knowledge.
The corresponding author of a paper on whether “a sense of shame heightens the desire for money” has retracted it, he claims, after being unable to repeat his analysis to try to fix an issue in the study.
The study, “Sirtuin 2 (SIRT2) enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced nigrostriatal damage via deacetylating forkhead box O3a (Foxo3a) and activating Bim protein,” by Gizem Donmez and colleagues, had already been subject to an extensive correction in May: Read the rest of this entry »